Ozmosi | Tarenflurbil Drug Profile

Product Description

Mechanisms of Action: JNK Activator

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Oral, Topical

FDA Designation: *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Myrexis
Company Location:
Company CEO:
Additional Commercial Interests: None

Clinical Description

Countries in Clinic:

Active Clinical Trial Count:

Recent & Upcoming Milestones

Highest Development Phases

Phase 3: Alzheimer Disease

Phase 2: Prostate Cancer|Multiple Sclerosis, Relapsing-Remitting|Skin Cancer|Melanoma|Dermatitis, Atopic

Phase 1: Healthy Volunteers

Trial ID	Trial	Phase	Trial Status	Disease	Primary Completion Date	Latest Trial Update Date	Data Updated
NCT02206854	FLIP0112	P1	Completed	Healthy Volunteers	2014-09-01	2019-03-20	Treatments
2014-004483-38	2014-004483-38	P2	Completed	Multiple Sclerosis, Relapsing-Remitting	2018-04-20	2025-07-09	Treatments
NCT02686788	TMP001_MS	P2	Completed	Multiple Sclerosis, Relapsing-Remitting	2018-04-01	2019-03-20	Treatments
2011-002571-42	2011-002571-42	P2	Completed	Dermatitis, Atopic	2012-04-19	2025-07-02	Treatments
NCT00045123	CDR0000256371	P2	Unknown status	Prostate Cancer	None	2019-03-21	Treatments
ACTRN12606000192583	ACTRN12606000192583	P2	Completed	Skin Cancer\|Melanoma	None	2024-04-03	Treatments
2006-000654-43	2006-000654-43	P3	Completed	Alzheimer Disease	2008-10-31	2022-03-12	Treatments
NCT00105547	MPC-7869-04-005.02	P3	Completed	Alzheimer Disease	None	2019-03-21	Treatments
NCT00380276	MPC-7869-05-009	P3	Terminated	Alzheimer Disease	None	2019-03-21	Treatments
NCT00322036	MPC-7869-05-010.01	P3	Terminated	Alzheimer Disease	None	2019-03-21	Treatments
2007-003362-17	2007-003362-17	P3	Active, not recruiting	Alzheimer Disease	None	2022-03-12	Treatments

Recent News Events

Date	Type	Title
06/15/2023	PubMed	Topological effects in ultrafast photoinduced processes between flurbiprofen and tryptophan in linked dyads and within human serum albumin.
04/01/2023	PubMed	Comparison of in vivo pharmacokinetic behaviors of R- and S-flurbiprofen after intravenous injection of flurbiprofen axetil.
06/01/2022	PubMed	Comparison of percutaneous permeation profiles of flurbiprofen enantiomers.

Did PRYZM just deliver the data you were looking for?
Did you try our Excel download too?

Now that you've used PRYZM, we hope you're able to see for yourself that it was designed and developed by people who actually use this data for a living. By applying next-generation technology for aggregating and curating this info across multiple key sources PRYZM delivering the latest information at your fingertips just the way you need it and with industry leading speed and cost effectiveness.

Our subscribers enjoy unlimited searches and receive this data on their own secure instance so they can overlay any additional internal/proprietary data on top of the search results and blend that data with real-time industry intel from PRYZM. Discover how you can continue to uncover the competitive landscape and drive strategy.

Suggestions

Session Expiring Soon

Tarenflurbil

Alternative Names: tarenflurbil, r-flurbiprofen, mpc-7869, TMP-001, TMP001, TMP 001 Clinical Status: Inactive Latest Update: 2023-06-15 Latest Update Note: PubMed Publication